BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Core Viewpoint - BioXcel Therapeutics, Inc. is leveraging artificial intelligence to develop innovative medicines in neuroscience and immuno-oncology, with upcoming presentations at the 2024 ASCP Annual Meeting highlighting their research efforts [1][10]. Presentation Details - Oral Presentation: "An Exploratory Comparison of Sublingual Dexmedetomidine with Quetiapine in Healthy Elderly Subjects" scheduled for May 28, 2024, from 2:20-2:30 p.m. ET at Salon 3 [2]. - Poster Presentation: "Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of BXCL501 with Concomitant Treatment with Anti-Depressant in Healthy Volunteers" on May 29, 2024, from 11:15 a.m.-1:00 p.m. ET at Salon 4 [2]. - Poster Presentation: "A Phase Ib/II Multicenter, Randomized, Double Blind, Placebo-Controlled, Ascending Dose Finding Study of BXCL501 in Agitation Associated with Dementia" on May 30, 2024, from 12:30-2:15 p.m. ET at Salon 4 [2]. Product Information - BXCL501 is an investigational sublingual film formulation of dexmedetomidine, targeting agitation in neuropsychiatric disorders, currently under investigation for various conditions including agitation associated with dementia and bipolar disorders [3]. - BXCL501 has received Breakthrough Therapy designation from the FDA for treating agitation associated with dementia and Fast Track designation for agitation related to schizophrenia and bipolar disorders [3]. Company Overview - BioXcel Therapeutics, Inc. focuses on drug re-innovation by utilizing existing approved drugs and machine learning algorithms to identify new therapeutic indications [10].